Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Effect of nusinersen after 3 years of treatment in 57 young children with SMA in terms of SMN2 copy number or type. | Arch Pediatr | 2024 | 38135619 | PubTator, text mining | PubMed |
| Self-Reported Health-Related Quality of Life of Children with Spinal Muscular Atrophy: Preliminary Insights from a Nationwide Patient Registry in Germany. | J Neuromuscul Dis | 2024 | 38108360 | PubTator, text mining | PubMed |
| Comparison of the accuracy of multiplex digital PCR versus multiplex ligation-dependent probe amplification in quantification of the survival of motor neuron genes copy numbers. | Clin Chim Acta | 2024 | 38097128 | PubTator, text mining | PubMed |
| Risdiplam Real World Data - Looking Beyond Motor Neurons and Motor Function Measures. | J Neuromuscul Dis | 2024 | 38073396 | PubTator, text mining | PubMed |
| Monitoring Nusinersen Treatment Effects in Children with Spinal Muscular Atrophy with Quantitative Muscle MRI. | J Neuromuscul Dis | 2024 | 38073395 | PubTator, text mining | PubMed |
| Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy. | Nat Biomed Eng | 2024 | 38057426 | PubTator, text mining | PubMed |
| Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data. | J Neuromuscul Dis | 2024 | 37980678 | PubTator, text mining | PubMed |
| Impaired Neurodevelopment in Children with 5q-SMA - 2 Years After Newborn Screening. | J Neuromuscul Dis | 2024 | 37927272 | PubTator, text mining | PubMed |
| Antisense therapy: a potential breakthrough in the treatment of neurodegenerative diseases. | Neural Regen Res | 2024 | 37862205 | PubTator, text mining | PubMed |
| Mitochondria replacement from transplanted amniotic fluid stem cells: a promising therapy for non-neuronal defects in spinal muscular atrophy. | Neural Regen Res | 2024 | 37862193 | PubTator, text mining | PubMed |
Application of a Multiplex Ligation-Dependent Probe Amplification-Based Next-Generation Sequencing Approach for the Detection of Pathogenesis of Duchenne Muscular Dystrophy and Spinal Muscular Atrophy Caused by Copy Number Aberrations. | Mol Neurobiol | 2024 | 37596438 | PubTator, text mining | PubMed |
| An Update on the Application of CRISPR Technology in Clinical Practice. | Mol Biotechnol | 2024 | 37269466 | PubTator, text mining | PubMed |
| Clinical SMN1 and SMN2 Gene-Specific Sequencing to Enhance the Clinical Sensitivity of Spinal Muscular Atrophy Diagnostic Testing. | Hum Mutat | 2023 | 40225149 | PubTator, text mining | PubMed |
| Spinal muscular atrophy in Ghanaian children confirmed by molecular genetic testing: a case series. | Pan Afr Med J | 2023 | 38282771 | PubTator, text mining | PubMed |
| A MALDI-TOF mass spectrometry-based method for detection of copy number variations in BRCA1 and BRCA2 genes. | Front Mol Biosci | 2023 | 38274092 | PubTator, text mining | PubMed |
| Autophagy in spinal muscular atrophy: from pathogenic mechanisms to therapeutic approaches. | Front Cell Neurosci | 2023 | 38259504 | PubTator, text mining | PubMed |
| Cooperation and Competition of RNA Secondary Structure and RNA-Protein Interactions in the Regulation of Alternative Splicing. | Acta Naturae | 2023 | 38234601 | PubTator, text mining | PubMed |
| Synthetic Approaches to Piperazine-Containing Drugs Approved by FDA in the Period of 2011-2023. | Molecules | 2023 | 38202651 | PubTator, text mining | PubMed |
| Nusinersen demonstrates effectiveness in treating spinal muscular atrophy: findings from a three-year nationwide study in Korea. | Front Neurol | 2023 | 38192577 | PubTator, text mining | PubMed |
| Paradoxical increase of neurofilaments in SMA patients treated with onasemnogene abeparvovec-xioi. | Front Neurol | 2023 | 38162454 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=19